Diurnal is a clinical stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead candidates are targeted at rare diseases with unmet medical need, with the aim of building a long-term ‘Adrenal Franchise’. Following successful completion of a Phase III trial, Infacort has been submitted to the European regulator for approval. Meanwhile, management is establishing the appropriate commercial infrastructure in preparation for launch in 2018. Trials with Chronocort for adults are continuing in Europe. Additional trials are required for approval of both products in the US, which are due to commence in 2H’17.